Ozempic was originally made to treat type 2 diabetes. The FDA first approved it on December 5, 2017, specifically as a weekly injection to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise. Its rise as a weight loss drug came later, after researchers noticed significant weight loss during the diabetes trials.
How Ozempic Was Developed
The story behind Ozempic starts at Novo Nordisk, the Danish pharmaceutical company, where researchers began working on the drug’s active ingredient, semaglutide, around 2002. The project grew out of a push to engineer new protein-based treatments for metabolic disease, led by chemists who spent years refining compounds that could mimic a natural gut hormone called GLP-1.
GLP-1 is a hormone your body releases after eating. It signals your pancreas to produce more insulin when blood sugar rises, and it simultaneously tells your pancreas to dial back glucagon, a hormone that triggers your liver to release stored sugar. The net effect is that blood sugar comes down after a meal. The problem is that natural GLP-1 breaks down in the body within minutes, making it useless as a medication on its own. The challenge for Novo Nordisk’s team was building a version that lasted long enough to work as a once-weekly injection.
Semaglutide was their answer. It binds to the same receptors as natural GLP-1 but is engineered to resist breakdown, staying active in the body for roughly a week. When it locks onto those receptors on pancreatic cells, it kicks off a chain of signals that ultimately causes insulin-containing packets inside cells to release their contents into the bloodstream. At the same time, it suppresses glucagon. Both actions work together to pull blood sugar levels down.
The Diabetes Results That Led to Approval
Ozempic earned its FDA approval based on the SUSTAIN clinical trial program, a series of large studies testing semaglutide in people with type 2 diabetes. The results were striking: patients taking 1.0 mg of semaglutide once weekly saw their HbA1c (a measure of average blood sugar over roughly three months) drop by 1.5% to 1.8% after 30 to 56 weeks. For context, a reduction of even 1% in HbA1c is considered clinically meaningful, so these numbers represented a significant improvement over many existing treatments.
The drug’s ability to lower blood sugar only when glucose levels are elevated is an important feature. Unlike some older diabetes medications, semaglutide carries a lower risk of pushing blood sugar dangerously low because its insulin-boosting effect is glucose-dependent. It ramps up when blood sugar is high and backs off when levels are normal.
How Weight Loss Entered the Picture
During the SUSTAIN diabetes trials, researchers noticed something they hadn’t set out to study: patients on semaglutide were losing a meaningful amount of weight. This wasn’t entirely unexpected, since GLP-1 also acts on appetite centers in the brain, slowing stomach emptying and reducing hunger. But the degree of weight loss caught attention and prompted dedicated studies.
Those studies eventually led to Wegovy, which is the same molecule (semaglutide) packaged under a different brand name and approved at a higher dose specifically for weight management. The maximum recommended dose of Wegovy is 2.4 mg per week, compared to 2.0 mg for Ozempic. Novo Nordisk kept the two brands separate because they target different conditions and use different dosing schedules, but the underlying drug is identical.
Cardiovascular Benefits Beyond Blood Sugar
The story didn’t end with diabetes and weight loss. Large-scale trials revealed that semaglutide also reduces the risk of serious heart problems. The SELECT trial enrolled over 17,600 patients with obesity and established cardiovascular disease (but not diabetes) and found that semaglutide cut the rate of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by 20% compared to placebo. Participants also lost an average of 8.5 percentage points more body weight than those on placebo.
Interestingly, about one-third of the heart benefit appeared to come from reductions in waist circumference rather than weight loss alone. This suggests the drug may be doing something beyond simply helping people shed pounds, potentially reducing the kind of deep abdominal fat that is most strongly linked to heart disease. The cardiovascular benefits were consistent across all starting weights and waist sizes, meaning both heavier and lighter participants saw protection.
From Diabetes Drug to Cultural Phenomenon
Ozempic’s original purpose was straightforward: help people with type 2 diabetes manage their blood sugar. It was designed by chemists, tested in diabetes-focused trials, and approved for that single indication. The weight loss that made it a household name was, in a sense, a side effect that proved significant enough to justify an entirely new product line. Today, semaglutide is approved for type 2 diabetes (as Ozempic), chronic weight management (as Wegovy), and carries data supporting cardiovascular protection in people with obesity. But its roots are firmly in diabetes research that began in a Danish lab more than two decades ago.